These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 32132091)

  • 1. Characterization of Antineovascularization Activity and Ocular Pharmacokinetics of Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GNE-947.
    Liu X; Liang X; LeCouter J; Ubhayakar S; Chen J; Cheng J; Lee T; Lubach J; Nonomiya J; Shahidi-Latham S; Quiason C; Solon E; Wright M; Hop CECA; Heffron TP
    Drug Metab Dispos; 2020 May; 48(5):408-419. PubMed ID: 32132091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockage of PI3K/mTOR Pathways Inhibits Laser-Induced Choroidal Neovascularization and Improves Outcomes Relative to VEGF-A Suppression Alone.
    Ma J; Sun Y; López FJ; Adamson P; Kurali E; Lashkari K
    Invest Ophthalmol Vis Sci; 2016 Jun; 57(7):3138-44. PubMed ID: 27304845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Species differences in ocular pharmacokinetics and pharmacological activities of regorafenib and pazopanib eye-drops among rats, rabbits and monkeys.
    Horita S; Watanabe M; Katagiri M; Nakamura H; Haniuda H; Nakazato T; Kagawa Y
    Pharmacol Res Perspect; 2019 Dec; 7(6):e00545. PubMed ID: 31763044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and pharmacokinetics of intravitreal 2-methoxyestradiol implants in normal rabbit and pharmacodynamics in a rat model of choroidal neovascularization.
    Robinson MR; Baffi J; Yuan P; Sung C; Byrnes G; Cox TA; Csaky KG
    Exp Eye Res; 2002 Feb; 74(2):309-17. PubMed ID: 11950241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications.
    Stahl A; Stumpp MT; Schlegel A; Ekawardhani S; Lehrling C; Martin G; Gulotti-Georgieva M; Villemagne D; Forrer P; Agostini HT; Binz HK
    Angiogenesis; 2013 Jan; 16(1):101-11. PubMed ID: 22983424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apatinib, an Inhibitor of Vascular Endothelial Growth Factor Receptor 2, Suppresses Pathologic Ocular Neovascularization in Mice.
    Kim KL; Suh W
    Invest Ophthalmol Vis Sci; 2017 Jul; 58(9):3592-3599. PubMed ID: 28715845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of dosage form on the intravitreal pharmacokinetics of diclofenac.
    Durairaj C; Kim SJ; Edelhauser HF; Shah JC; Kompella UB
    Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4887-97. PubMed ID: 19516015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiangiogenic effect of dasatinib in murine models of oxygen-induced retinopathy and laser-induced choroidal neovascularization.
    Seo S; Suh W
    Mol Vis; 2017; 23():823-831. PubMed ID: 29225458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of choroidal neovascularization using intravitreal bevacizumab.
    Pedersen R; Soliman W; Lund-Andersen H; Larsen M
    Acta Ophthalmol Scand; 2007 Aug; 85(5):526-33. PubMed ID: 17511757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-angiogenic properties of rapamycin on human retinal pericytes in an in vitro model of neovascular AMD via inhibition of the mTOR pathway.
    Asani B; Siedlecki J; Wertheimer C; Liegl R; Wolf A; Ohlmann A; Priglinger S; Priglinger C
    BMC Ophthalmol; 2022 Mar; 22(1):138. PubMed ID: 35337287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of HM-3 after intravitreal administration in mice.
    Yuan D; Shen H; Yuan S; Liu X; Xia X; Xie P; Li W; Hu J; Liu Q; Xu H
    Curr Eye Res; 2014 Aug; 39(8):837-44. PubMed ID: 24559456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Experimental Choroidal Neovascularization by a Novel Peptide Derived from Calreticulin Anti-Angiogenic Domain.
    Bee YS; Ma YL; Chen J; Tsai PJ; Sheu SJ; Lin HC; Huang H; Liu GS; Tai MH
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30274378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization.
    Zhu Q; Ziemssen F; Henke-Fahle S; Tatar O; Szurman P; Aisenbrey S; Schneiderhan-Marra N; Xu X; ; Grisanti S
    Ophthalmology; 2008 Oct; 115(10):1750-5, 1755.e1. PubMed ID: 18708261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment.
    Krzystolik MG; Afshari MA; Adamis AP; Gaudreault J; Gragoudas ES; Michaud NA; Li W; Connolly E; O'Neill CA; Miller JW
    Arch Ophthalmol; 2002 Mar; 120(3):338-46. PubMed ID: 11879138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of intravitreal bevacizumab (Avastin).
    Bakri SJ; Snyder MR; Reid JM; Pulido JS; Singh RJ
    Ophthalmology; 2007 May; 114(5):855-9. PubMed ID: 17467524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical evaluation of the novel small-molecule integrin alpha5beta1 inhibitor JSM6427 in monkey and rabbit models of choroidal neovascularization.
    Zahn G; Vossmeyer D; Stragies R; Wills M; Wong CG; Löffler KU; Adamis AP; Knolle J
    Arch Ophthalmol; 2009 Oct; 127(10):1329-35. PubMed ID: 19822850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the effects between intravitreal and periocular injections of adenoviral vectored pigment epithelium-derived factor on suppressing choroidal neovascularization in rats.
    Yan H; Cui J; Wang Y; Yu Y
    Ophthalmic Res; 2013; 49(2):81-9. PubMed ID: 23257710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-angiogenic effects of a mutant endostatin: a new prospect for treating retinal and choroidal neovascularization.
    Bai Y; Zhao M; Zhang C; Li S; Qi Y; Wang B; Huang L; Li X
    PLoS One; 2014; 9(11):e112448. PubMed ID: 25380141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ocular Safety of Intravitreal Propranolol and Its Efficacy in Attenuation of Choroidal Neovascularization.
    Nourinia R; Rezaei Kanavi M; Kaharkaboudi A; Taghavi SI; Aldavood SJ; Darjatmoko SR; Wang S; Gurel Z; Lavine JA; Safi S; Ahmadieh H; Daftarian N; Sheibani N
    Invest Ophthalmol Vis Sci; 2015 Dec; 56(13):8228-35. PubMed ID: 26720475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Lenvatinib, a multitargeted tyrosine kinase inhibitor, on laser-induced CNV mouse model of neovascular AMD.
    Wei X; Zhang T; Yao Y; Zeng S; Li M; Xiang H; Zhao C; Cao G; Li M; Wan R; Yang P; Yang J
    Exp Eye Res; 2018 Mar; 168():2-11. PubMed ID: 29284110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.